Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

Surbhi Sidana; Mayur Narkhede; Paul Elson; Debbie Hastings; Beth Faiman; Jason Valent; Christy Samaras; Kimberly Hamilton; Hien K. Liu; Mitchell R. Smith; Frederic J. Reu

doi:10.1371/journal.pone.0172996

Loading metrics

Open Access

Peer-reviewed

Research Article

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

Surbhi Sidana,

Current Address: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

Affiliation Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Mayur Narkhede,

Current Address: Department of Hematology & Medical Oncology, Georgetown University, Washington, District of Columbia, United States of America

Affiliation Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Paul Elson,

Affiliation Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Debbie Hastings,

Affiliation Department of Cancer Center Research, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Beth Faiman,

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Jason Valent,

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Christy Samaras,

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Kimberly Hamilton,

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Hien K. Liu,

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Mitchell R. Smith,

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯
Frederic J. Reu

* E-mail: reuf@ccf.org

Affiliation Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
⨯

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

Surbhi Sidana,
Mayur Narkhede,
Paul Elson,
Debbie Hastings,
Beth Faiman,
Jason Valent,
Christy Samaras,
Kimberly Hamilton,
Hien K. Liu,
Mitchell R. Smith

Published: March 9, 2017
https://doi.org/10.1371/journal.pone.0172996

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Neuropathy
Is the Subject Area "Neuropathy" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Intravenous injections
Is the Subject Area "Intravenous injections" applicable to this article?

Thanks for your feedback.
Amyloidosis
Is the Subject Area "Amyloidosis" applicable to this article?

Thanks for your feedback.
Multiple myeloma
Is the Subject Area "Multiple myeloma" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Routes of administration
Is the Subject Area "Routes of administration" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.